Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EDP1815 in mild to moderate plaque psoriasis
NCT04603027Phase 2Completed
- Sponsor
- Evelo Biosciences
- Start
- Sep 2020
- Primary completion
- Jul 2021
- Modality
- Microbiome Therapeutics
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial of EDP1815 in plaque psoriasis (4 arms), sponsored by Evelo Biosciences. Primary endpoint: Mean Percentage Change in Psoriasis Area and Severity Index at 16 weeks. Started Sep 2020; status: completed.
02
Drugs
EDP1815
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT04603027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04603027.